New gel could help heal wounds in rare skin disease
NCT ID NCT06917690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds every few days for 45 days, with follow-up visits every two weeks. The goal is to see if the gel helps wounds close faster and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Oleogel-S10 (a topical gel)
- What this could lead to
- If successful, this gel could become a treatment option to help close and heal skin wounds in people with epidermolysis bullosa, reducing pain and infection risk.
- What could go wrong
- This is a small, early-phase trial with only 6 participants, so results may not apply to everyone. The gel may not work for all wound types, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 6 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 days and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female aged ≥ 21 days 2. Confirmed diagnosis of either JEB or DEB 3. Both biological parents and all 4 grandparents of Japanese descent 4. At least 3 EB wounds that meet the following criteria at the time of enrollment: * All are located outside of the anogenital region * All are distinguishable from any other wounds on the subject's body (separated by a minimum of 5 cm) * At least one has been present for a minimum of 21 days but less than 9 months AND is 10 cm2 to 50 cm2 in size * At least two have been present for a minimum of 21 days but less than 9 months AND/OR are 10 cm2 to 50 cm2 in size 5. A female subject must meet one of the following criteria: * If of childbearing potential, she must: 1. Have a negative pregnancy test result at Screening and Baseline Visits, AND 2. Agree to use one of the following highly reliable methods of contraception from the day of the informed consent signature until the day after the last Oleogel- S10 application. The following methods are acceptable: * Placement of an intrauterine device (IUD) or intrauterine releasing system (IUS) * Combined (both estrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom) * Bilateral tubal occlusion * Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period * Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success * Be of non-childbearing potential, defined as one of the following: * Pre-menarche, OR * Post-menopausal (12 consecutive months of amenorrhea without an alternative medical cause), OR * Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required) 6. Subject and/or subject's legal representative has been informed about the study, has read and understood the information provided, and has given written informed consent 7. Subject and/or subject's legal representative is able and willing to follow all study procedures and instructions Exclusion Criteria: 1. Hypersensitivity to Oleogel-S10 or any of its excipients 2. Diagnosis of EB subtypes simplex or Kindler EB 3. Receipt of systemic antibiotics for wound-related infections within 7 days prior to enrollment 4. Receipt of systemic or topical (on EB wounds) steroids within 30 days prior to enrollment Exceptions: Inhaled, ophthalmic, or mucosal applications, such as budesonide suspension for esophageal strictures 5. Receipt of immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrollment Note: Dupilumab to manage pruritis is allowed if the subject has been on a stable dose for more than 3 months prior to baseline 6. Receipt of systemic gene therapy for the treatment of inherited EB 7. Receipt of short-acting stem cell therapy (infusion of Muse cells, allogeneic adipocyte-derived MSC sheet (topically applied), TEMCELL (allogeneic MSCs, subcutaneous injection)) within 6 months prior to study enrollment 8. Receipt of topical gene therapy for the treatment of inherited EB (e.g., beremagene geperpavec) within 3 months prior to enrollment 9. Receipt of a JACE® skin graft on any of the target wounds 10. Current and/or former malignancy, including skin malignancies such as basal cell carcinoma and squamous cell carcinoma 11. Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until study participation ends 12. Enrollment in any other interventional study or treated with any other investigational drug for any disease within 4 weeks prior to enrollment 13. Presence of any factor in the subject and/or legal representative that could interfere with study compliance, such as the ability to attend the scheduled study visits or to properly manage the dressing changes at home
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Collagen diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fukuoka Children's Hospital - Dermatology
RECRUITINGFukuoka, Japan
-
Hokkaido University Hospital
RECRUITINGSapporo, Japan
-
Kobe University Hospital
RECRUITINGKobe, Japan
-
Kurume University Hospital
RECRUITINGFukuoka, Japan
-
Niigata University Medical and Dental Hospital
RECRUITINGNiigata, Japan
-
Toho University Omori Medical Center
RECRUITINGŌta-ku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 150,000 children to be tracked from birth to old age in massive health study
- Staph bacteria may hold clues to painful skin rashes in IBD patients on Anti-TNF therapy
- Does dolutegravir raise the risk of birth defects? eswatini study investigates
- Can AI learn to spot endometriosis and fibroids on ultrasound?
- Apple peptides may speed skin healing after cosmetic procedures
- Can tiny tablets replace protein powder for kids with PKU?